Heart Failure (HF)HFcAFNCT07436299
Novel Technologies to Improve Echocardiographic Estimates of Left Ventricular Filling Pressure in Heart Failure Combined With Atrial Fibrillation
An observational study of Heart Failure (HF) and Atrial Fibrillation (AF), run by Oslo University Hospital at 15 sites in 10 countries.
Trial summary
Heart failure and atrial fibrillation are two of the most common heart diseases globally. Nearly half of all patients with heart failure also have atrial fibrillation. When heart failure and atrial fibrillation occur together, the risk of hospitalization and premature death increases significantly. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Heart Failure (HF), Atrial Fibrillation (AF)
- How many people
- 400 participants
- Where
- 15 sitesin 10 countries
- Study dates
- Sep 2026to Dec 2029
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with atrial fibrillation undergoing clinically indicated right or left heart catheterization.
Who may be able to join
- Atrial fibrillation (paroxysmal, persistent, or permanent)
- Scheduled for RHC or LHC for clinical reasons
- Able to undergo echocardiography and invasive pressure measurement within 8 hours
- No cardiovascular medication changes between echo and catheterization
- Written informed consent provided
Who cannot join
- Mitral stenosis or mitral annular calcification causing severe functional stenosis
- Severe mitral or severe tricuspid regurgitation
- Prosthetic mitral valve
- Atrial fibrillation with rapid ventricular response >120 bpm
- Suboptimal echocardiographic imaging
- Conditions rendering PCWP or LVEDP unreliable
Show all 11Show fewer
- Pregnant women
- Complex congenital heart disease
- LV assist device and patients with severe non-cardiac disease with poor prognosis
- Cardiac transplant patients
- End-stage liver disease
Trial locations and contacts
15 sites in 10 countries. Contact the study team or a site near you to ask about taking part.
15 sites in 10 countries
United States2 sites, 2 recruiting
- Not yet recruiting
Cleveland Clinic
Cleveland, Ohio, 44195
Tom Wang, MD, PhD, +1 440-823-2688, WANGT2@ccf.org
Joshua Latner, MD, +1 440-823-2688, latnerj@ccf.org
- Not yet recruiting
Methodist DeBakey Heart and Vascular Center
Houston, Texas, 77030
Bevon Lopez, +1 346-320-7421, balopez@houstonmethodist.org
Sherif Nagueh, MD, PhD, +1 713.441.1100, SNnagueh@houstonmethodist.org
Belgium2 sites, 2 recruiting
- Not yet recruiting
Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium
Aalst, 9300
Martin Penicka, MD, PhD, +32 53 72 41 68, martin.penicka@azorg.be
Hedwig Batjoens, +32 53 72 41 68, hedwig.batjoens@AZORG.be
- Not yet recruiting
Catholic University of Leuven
Leuven, 3000
Jens-Uwe Voigt, MD, PhD, +32 16 34 90 16, jens-uwe.voigt@uzleuven.be
Jens-Uwe Voigt, MD, PhD
France2 sites, 2 recruiting
- Not yet recruiting
Laboratory Signal Processing and Image, Department of Cardiology
Rennes, 35033
Erwan Donal, MD, PhD, +33 (0)2 23 23 62 20, erwan.donal@gmail.com
Erwan Donal, MD, PhD
- Not yet recruiting
Service de Cardiologie, Hôpitaux Universitaires de Strasbourg
Strasbourg, 67091
Elena Galli, MD, PhD, +33 03 88 11 67 68, gallelena@gmail.com
Elena Galli, MD, PhD
Japan2 sites, 2 recruiting
- Not yet recruiting
Nagoya City University Graduate School of Medical Sciences
Nagoya, Aichi-ken, 467-8601
Nobuyuki Ohte, MD, PhD, +81-90-4269-6549, ohte@812@gamail.com
Nobuyuki Ohte, MD, PhD
- Not yet recruiting
Ehime University
Tōon, Ehime, 791-0295
Katsuji Inoue, MD, PhD, +81 89-964-5111, katsujiinoue2@gmail.com
Katsuji Inoue, MD, PhD
United Kingdom2 sites, 2 recruiting
- Not yet recruiting
Department of Cardiovascular Sciences, University of Birmingham
Birmingham
Karina Bunting, PhD, MSc, BSc, +44 (0) 7500 872257, k.v.bunting@bham.ac.uk
Karina Bunting, PhD, MSc, BSc
- Not yet recruiting
King's College
London, WC2R2LS
Pablo Lamata, MSc, PhD, +44 (0)20 7836 5454, pablo.lamata@kcl.ac.uk
Joao Filipe Fernandes, MDc, PhD, +44 (0)20 7836 5454, jf.fernandes@kcl.ac.uk
New Zealand1 site, 1 recruiting
- Not yet recruiting
University of Auckland
Auckland, Auckland, 1010
Debbie Zhao, MSc, PhD, +64 9 373 7999, debbie.zhao@auckland.ac.nz
Martyn Nash, MSc, PhD, +6493737599 Ext.82550, martyn.nash@auckland.ac.nz
Norway1 site, 1 recruiting
- Recruiting
Division of Cardiovascular & Pulmonary Diseases, Oslo University Hospital
Oslo, Oslo, 0424
Lars Egil Reine Hammersboen, MD, 90116941, lerhammersboen@gmail.com
Otto Armin Smiseth, MD, PhD, +4790867189, otto.smiseth@gmail.com
Romania1 site, 1 recruiting
- Not yet recruiting
Carol Davila University of Medicine and Pharmacy
Bucharest, 020021
Bogdan Popescu, MD, PhD, +40 21 318 0719, bogdan.a.popescu@gmail.com
Bogdan Popescu, MD, PhD
Slovenia1 site, 1 recruiting
- Not yet recruiting
The Department of Cardiology at the Ljubljana University Medical Centre
Ljubljana, SI-1525
Marta Cvijic, MD, PhD, +386 1 522 50 50, marta.cvijic@gmail.com
Marta Cvijic, MD, PhD
South Korea1 site, 1 recruiting
- Not yet recruiting
Yonsei University College of Medicine
Seoul, Seoul, 03722
Jong-Won Ha, MD, PhD, +82-33-741-0211, JWHA@yuhs.ac
Jong-Won Ha, MD, PhD
About this study
Official title: Novel Technologies to Improve Echocardiographic Estimates of Left Ventricular Filling Pressure in Heart Failure Combined With Atrial Fibrillation: A Prospective Multicenter Study
Heart failure and atrial fibrillation are two of the most common heart diseases globally. Nearly half of all patients with heart failure also have atrial fibrillation. When heart failure and atrial fibrillation occur together, the risk of hospitalization and premature death increases significantly. However, there is a lack of reliable tools to assess how severely the heart is affected in these patients. This makes it difficult both to establish the correct diagnosis, tailor treatment, and predict who is at greatest risk of hospital admission or death from the disease.
One of the most important targets in heart failure is the filling pressure in the left ventricle. When this pressure is high, it means that the heart has difficulty receiving blood, leading to shortness of breath and fluid retention in the body. Today, filling pressure is usually estimated using ultrasound (echocardiography), but the available methods are primarily developed for patients without atrial fibrillation. In patients with both heart failure and atrial fibrillation, the measurements are so uncertain that they cannot be used as a reliable basis for clinical decision-making.
Read more
In this study, entitled Heart Failure combined with Atrial Fibrillation (HFcAF), the investigators will test new ultrasound methods that combine novel measures of cardiac chamber function with established techniques. Artificial intelligence will be used to identify the most useful combinations of parameters, select cardiac cycles that are best suited for analysis in atrial fibrillation, and automate and optimize the measurements. This approach may provide both more accurate and faster assessments, while also making the methods easier to implement in clinical practice. The aim is to improve the estimation of filling pressure so that it becomes more precise also in patients with atrial fibrillation. The investigators will then examine whether these improved methods can be used to predict which patients are at highest risk of hospitalization or death due to heart failure.
The study is designed as a prospective multicenter study, in which patients are recruited from several hospitals in different countries. This will make the results robust and generalizable to a wide range of patient populations. The investigators anticipate that the project will pave the way for better diagnostics and risk stratification in heart failure combined with atrial fibrillation and, in the longer term, contribute to improved guidelines and treatment for a large number of patients. If successful, the project will provide a new tool that can contribute to earlier and more targeted treatment, thereby improving quality of life and prognosis for a large group of patients.
Read the detailed description
Study Design:
This is a prospective, multicenter study of atrial fibrillation (AF) patients referred for right or left heart catheterization (RHC/LHC). The primary objective will be to develop and validate a clinically applicable algorithm combining echocardiographic and clinical parameters to differentiate normal from elevated left ventricular (LV) filling pressure (LVFP) in AF with ≥80% diagnostic accuracy. Secondary objectives will be to identify imaging predictors of abnormal pulmonary capillary wedge pressure (PCWP) elevation during exercise and to identify prognostic imaging markers associated with mortality and heart-failure outcomes over a 3-year follow-up period.
LVFP will be measured as PCWP during RHC and as LV end-diastolic pressure (LVEDP) during LHC. In cases studied during left atrial (LA) interventions, LA mean pressure will be used as a measure of LVFP. Echocardiography will be performed during, immediately before, or immediately after catheterization (≤8 hours separation, without cardiovascular medication changes). A dedicated exercise substudy will investigate imaging predictors of abnormal PCWP rise during exertion.
Recruitment of at least 400 patients is considered feasible based on experience from a previous international multicenter AF study. Patients will be recruited from 15 centers in the USA, Europe, Asia, and New Zealand over a period of 1.5 to 2 years.
Data collection:
A 12-lead electrocardiogram (ECG) and standard clinical data, including cuff blood pressure and standard blood tests with NT-proBNP, will be recorded.
Echocardiographic Imaging:
Echocardiographic measurements will be performed according to most recent American Society of Echocardiography / European Association of Cardiovascular Imaging guidelines. In addition, LA and right atrial (RA) strains will be measured. Echocardiographic recordings will be obtained by experienced investigators without knowledge of the invasive data. A core lab for echo analysis will be established. A minimum of 10 consecutive heartbeats will be recorded. Echo will be performed either simultaneously or within 8 hours of hemodynamic assessment. Equipment from different vendors will be used. Three-dimensional echocardiography will be used in selected patients.
Key Echocardiographic Views and Measurements
- Apical 4-chamber LV-focused: mitral inflow, tissue Doppler early diastolic velocity (e') (septal, lateral, average), systolic velocity (s'), isovolumetric relaxation time, LV global longitudinal strain (GLS), LV volumes and ejection fraction, LV mass
- Apical 4-chamber LA-focused: pulmonary vein Doppler (S and D velocities and their velocity-time integrals), LA strain, LA volumes
- Apical 5-chamber: aortic valve continuous-wave (CW) Doppler
- Apical 2- and 3-chamber: LV GLS, focused LV/LA imaging
- Right ventricular / pulmonary artery evaluation: tricuspid regurgitation velocity, right ventricular outflow tract (RVOT) pulsed-wave Doppler, RVOT acceleration time
- Subcostal inferior vena cava (IVC) view: IVC diameter and collapsibility.
- RA-focused view: RA reservoir strain
Cardiac Catheterization:
LVFP >15 mmHg will be considered elevated. LVFP will be averaged over 10 beats during end-expiration, using an index beat approach for selection of heart cycles.
Bicycle ergometer in supine position with simultaneous RHC will be performed in patients scheduled for this procedure as part of a diagnostic work-up and will be performed according to current clinical routine. This includes pressure measurements and focused echocardiographic study at rest and at peak exercise. The rate of pedaling will be 60 rotations per minute, and the workload will increase gradually to a moderate level.
Outcome Data:
All-cause mortality and heart failure hospitalizations will be the primary clinical outcomes. Outcome analysis will be extended to 3 years of follow-up.
Data Management and Analysis:
All imaging and invasive pressure measurements will be analyzed with investigators blinded to the corresponding data. Echocardiography will be reviewed centrally at the Echo Core Laboratory. Statistical analyses will include descriptive statistics, logistic regression, receiver operating characteristic curve analysis, and supervised machine-learning methods to derive a diagnostic algorithm. A two-sided P value <0.05 will be considered statistically significant.
Study Flowchart:
- Screening → 2. Consent → 3. Clinical assessment \& ECG → 4. Echocardiography → 5. RHC/LHC (± exercise) → 6. Data transfer to core labs → 7. Follow-up → 8. Analysis
- Conditions
- Heart Failure (HF), Atrial Fibrillation (AF)
- Keywords
- Heart failure, Atrial fibrillation, Echocardiography, Filling pressure, Diastolic function
- Medical subject headings
- Heart Failure, Atrial Fibrillation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Patients with atrial fibrillation referred for right- or left-heart catheterization | We will recruit patients >18 years with established or suspected heart failure who have atrial fibrillation and are referred to a diagnostic right- or left-sided heart catheterization or interventional procedures via the left atrium. Balanced numbers with normal and reduced left venticular ejection fraction, balanced representation of sexes, of short (<1year) and long-lasting duration of atrial fibrillation will be attempted. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Diagnostic accuracy of a non-invasive algorithm for classification of left ventricular filling pressure in atrial fibrillation
Main aim of the study is to develop and validate a clinically applicable algorithm combining echocardiographic and clinical parameters to differentiate normal from elevated LV filling pressure in AF with ≥80% diagnostic accuracy. Left venticular filling pressures will be measured during right- or left-sided heart catehterization and left ventricular filling pressure >15 mmHg will be considered elevated.
Measured: • Start recruitment: February 2026 • End recruitment: January 2028 • Follow-up: 3 years • Data analysis: Ferbuary 2026 - December 2028. Outcome analysis will be extended to 3 years of follow-up. • Manuscript preparation: December 2028 - December 2029
Imaging markers associated with mortality and heart-failure hospitalization in atrial fibrillation
To identify prognostic imaging markers associated with mortality and heart-failure hospitalization over a 3-year follow-up period.
Measured: • Start recruitment: February 2026 • End recruitment: January 2028 • Follow-up: 3 years • Data analysis: Ferbuary 2026 - December 2028. Outcome analysis will be extended to 3 years of follow-up. • Manuscript preparation: December 2028 - December 2029
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Feb 2026
- Study startSep 2026 (estimated)
- Primary completionJan 2028 (estimated)
- Study completionDec 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for Heart Failure (HF)Studies of the same condition, open and under way.
- More trials run by Oslo University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 400 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Oslo University Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- The National Association for Public Health, Norway
- Responsible party
- Principal investigator, Lars-Egil Hammersbøen, Oslo University Hospital
- Investigators
- Otto Armin Smiseth, Professor, Medical Doctor, Study chair, Oslo University HospitalThor Edvardsen, Professor, Medical Doctor, Study director, Oslo University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07436299
- Sponsor's protocol ID
- 964539
- Other IDs
- 52438
- Acronym
- HFcAF
- Status last verified
- Sep 2026
- First submitted
- 21 Feb 2026
- Last updated
- 10 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: De-identified individual participant data (IPD) underlying the results reported in this study, including the data dictionary, will be made available to qualified researchers upon reasonable request. Supporting documents, including the study protocol, statistical analysis plan, and analytic code, will also be available.
Publications
Nagueh SF, Sanborn DY, Oh JK, Anderson B, Billick K, Derumeaux G, Klein A, Koulogiannis K, Mitchell C, Shah A, Sharma K, Smiseth OA, Tsang TSM. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography and for Heart Failure With Preserved Ejection Fraction Diagnosis: An Update From the American Society of Echocardiography. J Am Soc Echocardiogr. 2025 Jul;38(7):537-569. doi: 10.1016/j.echo.2025.03.011.
PubMed 40617625Khan FH, Zhao D, Ha JW, Nagueh SF, Voigt JU, Klein AL, Gude E, Broch K, Chan N, Quill GM, Doughty RN, Young A, Seo JW, Garcia-Izquierdo E, Monivas-Palomero V, Mingo-Santos S, Wang TKM, Bezy S, Ohte N, Skulstad H, Beladan CC, Popescu BA, Kikuchi S, Panis V, Donal E, Remme EW, Nash MP, Smiseth OA. Evaluation of left ventricular filling pressure by echocardiography in patients with atrial fibrillation. Echo Res Pract. 2024 Jun 3;11(1):14. doi: 10.1186/s44156-024-00048-x.
PubMed 38825684Gomez-Outes A, Lagunar-Ruiz J, Terleira-Fernandez AI, Calvo-Rojas G, Suarez-Gea ML, Vargas-Castrillon E. Causes of Death in Anticoagulated Patients With Atrial Fibrillation. J Am Coll Cardiol. 2016 Dec 13;68(23):2508-2521. doi: 10.1016/j.jacc.2016.09.944.
PubMed 27931607Zafrir B, Lund LH, Laroche C, Ruschitzka F, Crespo-Leiro MG, Coats AJS, Anker SD, Filippatos G, Seferovic PM, Maggioni AP, De Mora Martin M, Polonski L, Silva-Cardoso J, Amir O; ESC-HFA HF Long-Term Registry Investigators. Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: a report from 14 964 patients in the European Society of Cardiology Heart Failure Long-Term Registry. Eur Heart J. 2018 Dec 21;39(48):4277-4284. doi: 10.1093/eurheartj/ehy626.
PubMed 30325423Jones NR, Smith M, Yang Y, Hobbs FDR, Taylor CJ. Trends in mortality in people with heart failure and atrial fibrillation: a population-based cohort study. Lancet Healthy Longev. 2025 Aug;6(8):100734. doi: 10.1016/j.lanhl.2025.100734. Epub 2025 Aug 13.
PubMed 40818479